Impact of COVID-19 on Monitoring of Therapeutic Unfractionated Heparin

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2020 Aug 21

PMID 32815032

Citations 4

Authors

Sarah K Adie

Nicholas Farina

Affiliations

Soon will be listed here.

Citing Articles

Pulmonary Thrombosis despite Therapeutic Anticoagulation in COVID-19 Pneumonia: A Case Report and Literature Review.

Niculae C, Gorea M, Tirlescu L, Constantin R, Moroti R, Hristea A Viruses. 2023; 15(7).

PMID: 37515221 PMC: 10386232. DOI: 10.3390/v15071535.

COVID-19 and coagulopathy.

Sarkar M, Madabhavi I, Quy P, Govindagoudar M Clin Respir J. 2021; 15(12):1259-1274.

PMID: 34399021 PMC: 8444678. DOI: 10.1111/crj.13438.

Thromboprophylaxis in COVID-19 - Rationale and considerations.

Bristogiannis S, Swan D, Thachil J Adv Biol Regul. 2021; 81:100819.

PMID: 34332403 PMC: 8299150. DOI: 10.1016/j.jbior.2021.100819.

COVID-19: coagulation disorders and anticoagulant treatment in patients hospitalised in ICU.

Pluta J, Cieniewicz A, Trzebicki J Anaesthesiol Intensive Ther. 2021; 53(2):153-161.

PMID: 34006056 PMC: 10158437. DOI: 10.5114/ait.2021.105783.

References

Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E . COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thromb Haemost. 2020; 120(6):998-1000. PMC: 7295272. DOI: 10.1055/s-0040-1710018. View

Tang N, Li D, Wang X, Sun Z . Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4):844-847. PMC: 7166509. DOI: 10.1111/jth.14768. View

Smither S, OBrien L, Eastaugh L, Woolley T, Lever S, Fletcher T . Haemostatic Changes in Five Patients Infected with Ebola Virus. Viruses. 2019; 11(7). PMC: 6669445. DOI: 10.3390/v11070647. View

Klok F, Kruip M, van der Meer N, Arbous M, Gommers D, Kant K . Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191:145-147. PMC: 7146714. DOI: 10.1016/j.thromres.2020.04.013. View

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z . Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18(5):1094-1099. PMC: 9906401. DOI: 10.1111/jth.14817. View

Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W . Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020; 382(17):e38. PMC: 7161262. DOI: 10.1056/NEJMc2007575. View

Borges A, OConnor J, Phillips A, Baker J, Vjecha M, Losso M . Factors associated with D-dimer levels in HIV-infected individuals. PLoS One. 2014; 9(3):e90978. PMC: 3953205. DOI: 10.1371/journal.pone.0090978. View

Vandiver J, Vondracek T . Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012; 32(6):546-58. DOI: 10.1002/j.1875-9114.2011.01049.x. View

Artim-Esen B, Pericleous C, Mackie I, Ripoll V, Latchman D, Isenberg D . Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. Arthritis Res Ther. 2015; 17:47. PMC: 4365552. DOI: 10.1186/s13075-015-0568-7. View

10.

Ramacciotti E, Agati L, Aguiar V, Wolosker N, Guerra J, de Almeida R . Zika and Chikungunya Virus and Risk for Venous Thromboembolism. Clin Appl Thromb Hemost. 2019; 25:1076029618821184. PMC: 6714924. DOI: 10.1177/1076029618821184. View

11.

Bikdeli B, Madhavan M, Jimenez D, Chuich T, Dreyfus I, Driggin E . COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(23):2950-2973. PMC: 7164881. DOI: 10.1016/j.jacc.2020.04.031. View